Provider: Ingenta Connect Database: Ingenta Connect Content: application/x-research-info-systems TY - ABST AU - Liu, Ning AU - Fang, Hao AU - Li, Yanling AU - Xu, Wenfang TI - Recent Research in Selective Cyclin-Dependent Kinase 4 Inhibitors for Anti-Cancer Treatment JO - Current Medicinal Chemistry PY - 2009-12-01T00:00:00/// VL - 16 IS - 36 SP - 4869 EP - 4888 KW - anti-cancer agents KW - tumor KW - CDK4 KW - G1-phase KW - Cell cycle KW - selective inhibitors KW - cyclin-dependent kinases N2 - It is well known that cyclins and cyclin-dependent kinases (CDKs) play essential roles in regulation of the cell cycle. In past two decades, the scientific researches suggest that the cyclin D1/ CDK4 complex is a key regulator of the transition through the G1 phase of the cell cycle. Moreover, deregulation of the cyclin D /CDK4 pathway has been identified in multiple tumor types. Thus, CDK4 is a genetically validated therapeutic target; hence, there has been a surge of interests in finding selective CDK4 inhibitors as anti-cancer agents. This review will give the recent progress in the studies of structure, functions of CDK4 and highly selective and potent CDK4 inhibitors. UR - https://www.ingentaconnect.com/content/ben/cmc/2009/00000016/00000036/art00009 M3 - doi:10.2174/092986709789909611 UR - https://doi.org/10.2174/092986709789909611 ER -